← All trials
NCT03246659
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2016
- Primary completion
- Nov 30, 2018
- Completion date
- Nov 30, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 25
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of PisaLead sponsor
- University of LjubljanaCollaborator
- University of FreiburgCollaborator
- Erasmus University RotterdamCollaborator
- University of PisaSponsor investigator
- University of PisaOverall official - principal investigator
- Medical University InnsbruckCollaborator
- INRASTES, NCSR Demokritos, Athens, GreeceCollaborator
- Jagiellonian UniversityCollaborator
- NATIONAL CENTRE FOR NUCLEAR RESEARCH, PolandCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.